IBU-tec advanced materials Valuation
Is IBU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IBU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IBU (€6.92) is trading above our estimate of fair value (€0.66)
Significantly Below Fair Value: IBU is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IBU?
Key metric: As IBU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is IBU's PS Ratio? | |
|---|---|
| PS Ratio | 0.7x |
| Sales | €48.84m |
| Market Cap | €32.97m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | 118.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IBU's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
SIM0 SIMONA | 0.6x | n/a | €354.0m |
BNN BRAIN Biotech | 1.2x | 8.5% | €68.8m |
NTG Nabaltec | 0.6x | 5.1% | €123.6m |
2HRA H&R GmbH KGaA | 0.1x | 2.7% | €127.3m |
IBU IBU-tec advanced materials | 0.7x | 19.2% | €33.0m |
Price-To-Sales vs Peers: IBU is expensive based on its Price-To-Sales Ratio (0.7x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does IBU's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: IBU is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is IBU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.7x |
| Fair PS Ratio | 0.8x |
Price-To-Sales vs Fair Ratio: IBU is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Compañía de Minas BuenaventuraA
US$3.1b
Engages in the exploration, development, construction, and operation of mineral processing business.
MBU
US$11.40
7D
-0.9%
1Y
37.3%
Arkema
€5.6b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.30
7D
-4.7%
1Y
-20.2%
Central Asia Metals
UK£276.3m
Operates as a base metals producer.
9C3
UK£1.86
7D
-0.5%
1Y
-4.1%